BR0210652A - Pirrolopirimidinas como inibidores de proteìnas cinases - Google Patents

Pirrolopirimidinas como inibidores de proteìnas cinases

Info

Publication number
BR0210652A
BR0210652A BR0210652-3A BR0210652A BR0210652A BR 0210652 A BR0210652 A BR 0210652A BR 0210652 A BR0210652 A BR 0210652A BR 0210652 A BR0210652 A BR 0210652A
Authority
BR
Brazil
Prior art keywords
protein kinase
kinase inhibitors
compounds
pyrrolopyrimidines
bioisteroids
Prior art date
Application number
BR0210652-3A
Other languages
English (en)
Inventor
Paul Joseph Cox
Tahir Nadeem Majid
Shelley Amendola
Stephanie Daniele Deprets
Chris Edlin
Brian Leslie Pedgrift
Frank Halley
Michael Edwards
Bernard Baudoin
Lain Mcfarlane Mclay
Davis John Aldous
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BR0210652A publication Critical patent/BR0210652A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

"PIRROLOPIRIMIDINAS COMO INIBIDORES DE PROTEìNAS CINASES". Esta invenção é dirigida aos compostos da fórmula (I), aos N-óxidos, pró-drogas, bioisósteros ácidos, sais ou solvatos farmaceuticamente aceitáveis de tais compostos, ou N-óxidos, pró-drogas, ou bioisósteros ácidos de tais sais ou solvatos, às composições compreendendo tais compostos, e aos métodos de tratamento compreendendo administrar, a um paciente estando necessitado dos mesmos, tais compostos e composições.
BR0210652-3A 2001-06-23 2002-06-21 Pirrolopirimidinas como inibidores de proteìnas cinases BR0210652A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
US30167801P 2001-06-28 2001-06-28
PCT/GB2002/002835 WO2003000695A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BR0210652A true BR0210652A (pt) 2004-08-10

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210652-3A BR0210652A (pt) 2001-06-23 2002-06-21 Pirrolopirimidinas como inibidores de proteìnas cinases

Country Status (22)

Country Link
EP (1) EP1404676A1 (pt)
JP (1) JP4344607B2 (pt)
CN (1) CN1294135C (pt)
AU (1) AU2002314325B8 (pt)
BR (1) BR0210652A (pt)
CA (1) CA2451932C (pt)
CZ (1) CZ20033443A3 (pt)
EA (1) EA007415B1 (pt)
EC (1) ECSP034922A (pt)
EE (1) EE05432B1 (pt)
GB (1) GB0115393D0 (pt)
HU (1) HUP0400300A3 (pt)
ME (1) MEP19308A (pt)
NZ (1) NZ529766A (pt)
OA (1) OA12632A (pt)
PL (1) PL374096A1 (pt)
RS (1) RS51698B (pt)
SK (1) SK15882003A3 (pt)
TN (1) TNSN03144A1 (pt)
TR (1) TR200302242T2 (pt)
UA (1) UA76760C2 (pt)
WO (1) WO2003000695A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
EP1687309A1 (en) 2003-11-17 2006-08-09 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
BRPI0416909A (pt) * 2003-11-25 2007-01-16 Pfizer Prod Inc método de tratamento de aterosclerose
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
FR2876103B1 (fr) * 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2878849B1 (fr) 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2607901C (en) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
EP3495369B1 (en) 2007-06-13 2021-10-27 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
NZ586642A (en) 2008-01-11 2012-04-27 Natco Pharma Ltd Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
PE20140407A1 (es) 2008-06-10 2014-04-25 Abbott Lab Nuevos compuestos triciclicos
MX2011012262A (es) 2009-05-22 2012-01-25 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
EA025520B1 (ru) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
TW201802091A (zh) * 2009-12-01 2018-01-16 艾伯維有限公司 新穎三環化合物
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
SG10201910912TA (en) 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
BR112013012502A2 (pt) 2010-11-19 2019-03-06 Incyte Corporation pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
CN102093364B (zh) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN103476776B (zh) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
DK2877467T3 (en) 2012-07-26 2017-02-13 Glaxo Group Ltd 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
EA030705B1 (ru) 2013-03-06 2018-09-28 Инсайт Холдингс Корпорейшн Способы и промежуточные соединения при получении ингибитора jak
AU2014244263A1 (en) 2013-03-13 2015-08-13 Abbvie Inc. CDK9 kinase inhibitors
BR112015021549A2 (pt) 2013-03-13 2017-07-18 Abbvie Inc inibidores de piridina cinase cdk9
WO2014151444A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
AU2014231567A1 (en) 2013-03-14 2015-10-01 Abbvie Inc. Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
JP2016512560A (ja) * 2013-03-14 2016-04-28 アッヴィ・インコーポレイテッド ピロロピリミジン系ｃｄｋ９キナーゼ阻害薬
ES2792549T3 (es) 2013-08-07 2020-11-11 Incyte Corp Formas de dosificación de liberación sostenida para un inhibidor de JAK1
CN104804001B9 (zh) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
SG10201913986YA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
WO2018165581A1 (en) 2017-03-09 2018-09-13 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
PL3746429T3 (pl) 2018-01-30 2022-06-20 Incyte Corporation Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu)
WO2019191684A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
EP3860998B1 (en) 2018-10-05 2023-12-27 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1441497A (en) * 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
BR9713552A (pt) * 1996-11-27 2000-01-25 Pfizer Derivados de pirimidina bicìclicos condensados
ID26698A (id) * 1998-06-19 2001-02-01 Pfizer Prod Inc SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CZ2001959A3 (cs) * 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
DK1235830T3 (da) * 1999-12-10 2004-03-29 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer

Also Published As

Publication number Publication date
CN1518552A (zh) 2004-08-04
ECSP034922A (es) 2004-04-28
JP2005508300A (ja) 2005-03-31
WO2003000695A1 (en) 2003-01-03
RS99203A (en) 2006-12-15
TR200302242T2 (tr) 2004-12-21
EA007415B1 (ru) 2006-10-27
NZ529766A (en) 2008-11-28
MEP19308A (en) 2010-06-10
JP4344607B2 (ja) 2009-10-14
CN1294135C (zh) 2007-01-10
SK15882003A3 (sk) 2004-07-07
HUP0400300A3 (en) 2010-12-28
HUP0400300A2 (en) 2007-08-28
AU2002314325B8 (en) 2009-01-29
AU2002314325B2 (en) 2009-01-08
RS51698B (en) 2011-10-31
EE200400003A (et) 2004-02-16
EP1404676A1 (en) 2004-04-07
CA2451932A1 (en) 2003-01-03
CA2451932C (en) 2009-12-29
EA200400073A1 (ru) 2004-08-26
PL374096A1 (en) 2005-09-19
GB0115393D0 (en) 2001-08-15
UA76760C2 (uk) 2006-09-15
TNSN03144A1 (en) 2005-12-23
EE05432B1 (et) 2011-06-15
CZ20033443A3 (en) 2004-03-17
WO2003000695A8 (en) 2004-03-11
OA12632A (en) 2006-06-14

Similar Documents

Publication Publication Date Title
BR0210652A (pt) Pirrolopirimidinas como inibidores de proteìnas cinases
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
TR200102782T2 (tr) Bisiklik heterosikleler, bu bileşikleri ihtiva eden farmasötik kompozisyonlar
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
BRPI0410170A (pt) preparação e uso de derivados de ácido aril alquìlico para o tratamento de obesidade
PT1235826E (pt) Acrilamidas de quinuclidina
EA200500853A1 (ru) 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
DE60205455D1 (de) Naphthyridinderivate
BR0207978A (pt) N-but-3enil norbuprenorfina e métodos de uso
DK1747220T3 (da) Substituerede 1H-pyrrolo[3,2-B, 3,2-C og 2,3-C]pyridin-2-carboxamider og relaterede analoger som inhibitorer af casein kinase I epsilon
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BR0013781A (pt) Pirazolo [4,3-d]pirimidinas
BR0213037A (pt) Derivados de pirimidina
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
MXPA04005809A (es) Inhibidores de proteinas quinasas.
PT1213289E (pt) Compostos de n-benzenossulfonil-l-prolina como antagonistas da bradiquinina
BR0114276A (pt) Derivados de benzodiazepina ou sais destes farmaceuticamente aceitáveis, agente para inibir o fator x de coagulação do sangue ativado, composição farmacêutica, e, inibidor da coagulação sanguìnea ou um agente para prevenir ou tratar a trombose ou o embolismo
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
BR9906719A (pt) "n-óxidos de compostos heterocìclicos com atividade inibidora de tnf e de pde-iv"
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 487/04, A61K 31/505, A61P 29/00

Ipc: C07D 487/04 (2006.01), A61K 31/519 (2006.01), A61K

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.